固本定喘方干预支气管哮喘患者神经内分泌免疫网络失衡的临床研究

Clinical Research of Gubendingchuan Decoction Intervening NEI Net Unbalance of Patients With Bronchial Asthma

目的观察固本定喘方干预支气管哮喘患者神经内分泌免疫网络失衡的疗效。方法将60例支气管哮喘患者随机分为中药组、西药组、对照组各20例。中药组采用固本定喘方治疗,西药组采用舒利迭治疗,对照组不给予任何药物治疗,仅在发作时给予解痉药物治疗,3组疗程均为疗程30d。结果中药组、西药组在治疗后临床症状计分均比治疗前有显著改善(P<0.05);中药组、西药组在治疗后各HPAA指标值均比治疗前有显著升高(P<0.05);中药组、西药组在治疗后白介素-4指标值均比治疗前有显著降低,干扰素-γ指标值比治疗前有显著升高(P<0.05)。结论固本定喘方能有效调节支气管哮喘患者神经内分泌免疫网络失衡,其疗效与西药组差别不大,而副作用则明显低于西药组。

Objective：To observe the curative effects of Gubendingchuan Decoction intervening NEI net unbalance of patients with bronchial asthma.Methods：60 patients with bronchial asthma were divided randomly into 3 groups,such as the TCM group with Gubendingchuan Decoction,the western medicine group with seretide and the control group with no medicine therapy.The treatment course was lasted for 30 days.Results：There were obvious differences before and after treatment in these groups （P 〈 0.05）.In the TCM group and the western medicine group,the HPAA indicators and the I FN-γ were increased,but the IL-4 were decreased after treatment （P 〈 0.05）.Conclusion：Gubendingchuan Decoction can effectively adjust NEI net unbalance of patients with bronchial asthma.There is no difference between the TCM group and the western medicine group.But its side effect is obviously lower than it in the western medicine group.